A richly priced buyout seriously boosted the share price of biotech Avidity Biosciences (NASDAQ: RNA) as the stock trading week began. The company’s equity rose by 42%, closing to land just below the buyout price. This leap looked quite impressive next to the S&P 500 (SNPINDEX: ^GSPC), as the bellwether stock indicator only increased by 1.2% on the day.
The purchasing party is global pharmaceutical company Novartis, which on Sunday divulged that it and Avidity had agreed to the acquisition. Under its terms, Switzerland-based Novartis will pay $72 per share for Avidity in an all-cash transaction. That’s 46% higher than Avidity’s closing share price last Friday.
Image source: Getty Images.
The boards of directors of both companies have unanimously approved the buyout, which values Avidity at around $12 billion.
Avidity was a tempting target for Novartis because it’s a next-generation biotech developing new RNA therapeutics known as Antibody Oligonucleotide Conjugates (AOCs) to battle genetic neuromuscular disorders.
The acquirer said that its ownership of Avidity’s current programs is “expected to advance the company’s neuroscience strategy and complement the current pipeline with potential first-in-class therapeutic candidates that address the genetic drivers of muscle-damaging conditions.”
The Avidity acquisition is expected to close in the first half of 2026; Novartis did not get more specific, although it did say it and Avidity would continue to operate as separate and independent businesses. The deal is subject to approval from the relevant regulatory bodies.
Before you buy stock in Avidity Biosciences, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Avidity Biosciences wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have…
..
